Aziyo Biologics, Inc. AZYO
We take great care to ensure that the data presented and summarized in this overview for AZIYO BIOLOGICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AZYO
View all-
Birchview Capital, LP Burlington, VT1.66MShares$2.4 Million2.06% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT1.65MShares$2.39 Million0.15% of portfolio
-
Perkins Capital Management Inc798KShares$1.16 Million1.0% of portfolio
-
Aigh Capital Management LLC Baltimore, MD437KShares$633,0200.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA416KShares$602,7790.0% of portfolio
-
Knollwood Investment Advisory, LLC Hunt Valley, MD409KShares$593,3730.23% of portfolio
-
Geode Capital Management, LLC Boston, MA118KShares$171,5480.0% of portfolio
-
Silverarc Capital Management, LLC78.6KShares$113,9410.04% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny35.6KShares$51,6430.0% of portfolio
-
Bank Of America Corp Charlotte, NC23.6KShares$34,1960.0% of portfolio
Latest Institutional Activity in AZYO
Top Purchases
Top Sells
About AZYO
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Insider Transactions at AZYO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 21
2024
|
C Randal Mills PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,019
-5.81%
|
$24,057
$3.5 P/Share
|
Jun 21
2024
|
C Randal Mills PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,473
+14.01%
|
-
|
Jun 10
2024
|
C Randal Mills PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
19,327
-14.33%
|
$57,981
$3.47 P/Share
|
Jun 10
2024
|
C Randal Mills PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
54,167
+28.66%
|
-
|
Jun 10
2024
|
Matthew Ferguson CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
8,920
-5.52%
|
$26,760
$3.47 P/Share
|
Jun 10
2024
|
Matthew Ferguson CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+13.39%
|
-
|
Jun 10
2024
|
Michelle Le Roux Williams CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
7,900
-31.6%
|
$23,700
$3.47 P/Share
|
Jun 10
2024
|
Michelle Le Roux Williams CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+50.0%
|
-
|
Mar 08
2024
|
Matthew Ferguson CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
528
-0.43%
|
$1,584
$3.24 P/Share
|
Mar 08
2024
|
Matthew Ferguson CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,288
+1.05%
|
-
|
Dec 28
2023
|
High Cape Capital, L.P. Director |
SELL
Other acquisition or disposition
|
Indirect |
1,436,077
-17.03%
|
-
|
Dec 28
2023
|
High Cape Capital, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,436,077
-17.03%
|
-
|
Sep 21
2023
|
Matthew Ferguson CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
70,053
+36.76%
|
-
|
Jun 21
2023
|
C Randal Mills PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,772
-11.03%
|
$15,544
$2.41 P/Share
|
Jun 21
2023
|
C Randal Mills PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,474
+24.18%
|
-
|
Apr 27
2023
|
C Randal Mills PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
44,947
+48.35%
|
-
|
Mar 27
2023
|
Birchview Capital, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.6%
|
$10,000
$1.59 P/Share
|
Mar 24
2023
|
Birchview Capital, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
20,000
+0.6%
|
$20,000
$1.35 P/Share
|
Mar 23
2023
|
Birchview Capital, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
110,000
+3.22%
|
$110,000
$1.49 P/Share
|
Mar 09
2023
|
Thomas Englese CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
289
-1.59%
|
$1,156
$4.3 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 70.1K shares |
---|---|
Exercise of conversion of derivative security | 128K shares |
Payment of exercise price or tax liability | 44.7K shares |
---|---|
Other acquisition or disposition | 2.87M shares |